| Literature DB >> 32939231 |
Johanna F Lindahl1,2,3, Tove Hoffman1, Mouna Esmaeilzadeh1, Björn Olsen4, Reidar Winter5, Stefan Amer6, Christian Molnár6, Ann Svalberg6, Åke Lundkvist1.
Abstract
The COVID-19 pandemic is growing and spread in the Swedish elderly care system during April 2020. The increasing number of employees on sick-leave due to COVID-19 created severe logistic problems. Some elderly care homes therefore started to screen their personnel to secure the safety of the elderly and to avoid unnecessary quarantine of potentially immune employees. Secondary data from a screening with a COVID-19 rapid test for detection of SARS-CoV-2-specific IgM and IgG of 1,005 employees in 22 elderly care homes in Stockholm, Sweden, were analyzed. Seropositive employees were found in 21 out of the 22 care homes. In total, 23% (231/1,005) of the employees tested positive for antibodies against SARS-CoV-2, and 14.3% (144/1,005) were found positive for IgM (either alone or combined with IgG), indicating recent or present infection. Of those that tested seropositive, 46.5% did not report any clinical symptoms, indicating pre- or asymptomatic infections. Reported symptoms with the highest correlation with seropositivity were fever and loss of smell and taste. These results suggest that antibody testing of employees in elderly care homes is valuable for surveillance of disease development and a crucial screening tool in the effort to decrease the death toll in this pandemic.Entities:
Keywords: COVID-19; IgG; IgM; SARS-CoV-2; elderly care homes; employees; rapid test
Year: 2020 PMID: 32939231 PMCID: PMC7480625 DOI: 10.1080/20008686.2020.1789036
Source DB: PubMed Journal: Infect Ecol Epidemiol ISSN: 2000-8686
Figure 1.Map of the incidence of laboratory-confirmed COVID-19 cases [25] in Sweden as of April 23 2020, with the location of Stockholm marked with a star.
Serological responses of 1,005 employees to SARS-CoV-2 at 22 different elderly care homes in Stockholm, Sweden, and the number of employees that reported known contacts with COVID-19 cases.
| Seropositive | IgM only | IgM and IgG | IgG only | Reported contact | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Home | Tested | Number | % | Number | % | Number | % | Number | % | Number | %* |
| 1 | 50 | 12 | 24.0 | 1 | 2.0 | 7 | 14.0 | 4 | 8.0 | 24/50 | 48.0 |
| 2 | 65 | 9 | 13.8 | 0 | 0.0 | 6 | 9.2 | 3 | 4.6 | 22/62 | 35.5 |
| 3 | 37 | 8 | 21.6 | 0 | 0.0 | 5 | 13.5 | 3 | 8.1 | 14/37 | 37.8 |
| 4 | 112 | 32 | 28.6 | 8 | 7.1 | 13 | 11.6 | 11 | 9.8 | 20/27 | 74.1 |
| 5 | 33 | 8 | 24.2 | 2 | 6.1 | 6 | 18.2 | 0 | 0.0 | 6/32 | 18.8 |
| 6 | 25 | 10 | 40.0 | 2 | 8.0 | 5 | 20.0 | 3 | 12.0 | 0/25 | 0.0 |
| 7 | 17 | 5 | 29.4 | 0 | 0.0 | 4 | 23.5 | 1 | 5.9 | 10/17 | 58.8 |
| 8 | 73 | 15 | 20.5 | 0 | 0.0 | 10 | 13.7 | 5 | 6.8 | ||
| 9 | 35 | 5 | 14.3 | 3 | 8.6 | 0 | 0.0 | 2 | 5.7 | ||
| 10 | 7 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | ||
| 11 | 44 | 17 | 38.6 | 3 | 6.8 | 14 | 31.8 | 0 | 0.0 | ||
| 12 | 11 | 2 | 18.2 | 0 | 0.0 | 2 | 18.2 | 0 | 0.0 | ||
| 13 | 60 | 9 | 15.0 | 0 | 0.0 | 2 | 3.3 | 7 | 11.7 | ||
| 14 | 51 | 11 | 21.6 | 1 | 2.0 | 5 | 9.8 | 5 | 9.8 | ||
| 15 | 42 | 19 | 45.2 | 4 | 9.5 | 8 | 19.0 | 7 | 16.7 | ||
| 16 | 80 | 15 | 18.8 | 1 | 1.3 | 7 | 8.8 | 7 | 8.8 | ||
| 17 | 73 | 21 | 28.8 | 5 | 6.8 | 3 | 4.1 | 13 | 17.8 | ||
| 18 | 22 | 4 | 18.2 | 1 | 4.5 | 1 | 4.5 | 2 | 9.1 | ||
| 19 | 68 | 9 | 13.2 | 1 | 1.5 | 1 | 1.5 | 7 | 10.3 | ||
| 20 | 19 | 2 | 10.5 | 1 | 5.3 | 0 | 0.0 | 1 | 5.3 | ||
| 21 | 46 | 17 | 37.0 | 5 | 10.9 | 6 | 13.0 | 6 | 13.0 | 29/46 | 63.0 |
| 22 | 35 | 1 | 2.9 | 1 | 2.9 | 0 | 0.0 | 0 | 0.0 | 0/35 | 0.0 |
* Out of those answering this question
Figure 2.Serological results (as percentages and absolute numbers) among employees at 22 elderly care homes in Stockholm, Sweden.
Prevalence of IgM (either only IgM or combined with IgG) or only IgG among elderly care home employees with or without reported symptoms.
| IgM positive (%) | IgG positive only (%) | ||
|---|---|---|---|
| Symptoms at sampling | Yes | 18/50 (36.0) | 6/50 (12.0) |
| No | 102/409 (24.9) | 73/409 (17.8) | |
| Symptom within the last month | Yes | 18/77 (23.4)* | 8/77 (10.4) |
| No | 33/254 (13.0) | 15/254 (5.9) | |
| Symptoms 1–2 months earlier | Yes | 2/21 (9.5) | 1/21 (4.8) |
| No | 49/310 (15.8) | 22/310 (7.1) |
*Significant at p < 0.05 compared to the row below.
Predictors for seropositivity in both univariable and multivariable analyses.
| Univariable | Multivariable | |||||
|---|---|---|---|---|---|---|
| Predictor | Seropositive (%) | |||||
| Yes | 125 | 40 (32.0) | 2.4 (1.3–4.4) | |||
| No | 206 | 33 (16.0) | ||||
| Aches | Yes | 11 | 4 (36.4) | 0.25 | Not included | |
| No | 324 | 70 (21.6) | ||||
| Anosmia/ageusia | Yes | 13 | 9 (69.2) | 6.4 (1.6-25.8) | ||
| No | 323 | 66 (20.4) | ||||
| Cold, sore throat | Yes | 41 | 14 (34.2) | 0.06 | Not included | |
| No | 297 | 63 (21.2) | ||||
| Cough | Yes | 37 | 12 (32.4) | 0.11 | Not included | |
| No | 298 | 62 (20.8) | ||||
| Dyspnea | Yes | 14 | 6 (42.9) | 0.06 | Not included | |
| No | 321 | 68 (21.2) | ||||
| Fever | Yes | 23 | 11 (47.8) | 2.8 (1.0–8.1) | ||
| No | 314 | 65 (20.7) | ||||
| Headache | Yes | 29 | 11 (37.9) | 0.04 | 0.4 (0.1–1.4) | 0.16 |
| No | 309 | 66 (21.4) | ||||
| Tired | Yes | 43 | 13 (30.2) | 0.18 | Not included | |
| No | 293 | 62 (21.2) | ||||
| Random effect of home | 0.3 (0.04–1.64) | |||||
p-Values < 0.05 of significance are indicated in bold.